ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02637999
Previous Study | Return to List | Next Study

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02637999
Recruitment Status : Completed
First Posted : December 22, 2015
Results First Posted : April 13, 2018
Last Update Posted : April 13, 2018
Sponsor:
Information provided by (Responsible Party):
Hepatera Ltd.

Brief Summary:
Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta virus (HDV).

Condition or disease Intervention/treatment Phase
Chronic Hepatitis D Infection Drug: PEG IFN alfa-2a Drug: Myrcludex B Phase 1 Phase 2

Detailed Description:

The study is designed to evaluate safety and efficacy of MXB in a subset of HBV infected patients who are co-infected with HDV. Hepatitis delta represents the most severe form of chronic viral hepatitis and there is no approved treatment option available for patients infected with both HBV and HDV.

24 patients will be randomised into 3 arms: pre-treatment with MXB followed by PEG-INF-a treatment versus a combination of both drugs versus PEG-INF-a.

Prolonged blockade of HBV entry into hepatocytes should also block infection with HDV particles (which uses hepatitis B surface antigen (HBsAg) as its envelope) and thus provide a therapeutic option for this otherwise hardly treatable disease. PEG-INF-a is used for the treatment of chronic hepatitis delta. The study endpoints are virological response (HBsAg, hepatitis delta virus ribonucleic acid (HDV RNA), hepatitis B virus deoxyribonucleic acid (HBV DNA)), as well as safety and tolerability and drug immunogenicity.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta
Actual Study Start Date : February 13, 2014
Actual Primary Completion Date : January 21, 2016
Actual Study Completion Date : January 21, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MXB then PEG IFN
Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks
Drug: PEG IFN alfa-2a
Other Name: Pegasys

Drug: Myrcludex B
Other Name: Myrcludex

Experimental: MXB + PEG IFN then PEG IFN
Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks
Drug: PEG IFN alfa-2a
Other Name: Pegasys

Drug: Myrcludex B
Other Name: Myrcludex

Active Comparator: PEG IFN
PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks
Drug: PEG IFN alfa-2a
Other Name: Pegasys




Primary Outcome Measures :
  1. Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 12 of Therapy [ Time Frame: Baseline and 12 weeks ]
    HBsAg response was defined as serum HBsAg decline of at least 0.5 log IU/mL (or HBsAg negativation) at week 12 compared to baseline (including the patient with negative baseline level)


Secondary Outcome Measures :
  1. Number of Participants With Hepatitis B Surface Antigen (HBsAg) Response at Week 24 of Therapy [ Time Frame: Baseline and 24 weeks ]
    HBsAg response was defined as serum HBsAg decline of at least 0.5 log IU/mL (or HBsAg negativation) at week 24 compared to baseline (including the patient with negative baseline level)

  2. Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 24 of Therapy [ Time Frame: Baseline and 24 weeks ]
    HBV DNA response was defined as persistent reduction of HBV DNA by > 1 log IU/mL or negativation (including the patient with negative baseline level)

  3. Number of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Response at Week 12 of Therapy [ Time Frame: Baseline and 12 weeks ]
    HBV DNA response was defined as persistent reduction of HBV DNA by > 1 log IU/mL or negativation (including the patient with negative baseline level)

  4. Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 12 of Therapy [ Time Frame: Baseline and 12 weeks ]
    HDV RNA response was defined as persistent reduction of HDV RNA by > 1 log IU/mL or negativation (including the patient with negative baseline level)

  5. Number of Participants With Hepatitis D Virus Ribonucleic Acid (HDV RNA) Response at Week 24 of Therapy [ Time Frame: Baseline and 24 weeks ]
    HDV RNA response was defined as persistent reduction of HDV RNA by > 1 log IU/mL or negativation (including the patient with negative baseline level)

  6. Number of Participants With Biochemical Response at Week 12 of Therapy [ Time Frame: Baseline and 12 weeks ]
    Biochemical response was defined as normalization of ALT level as compared to baseline.

  7. Number of Participants With Biochemical Response at Week 24 of Therapy [ Time Frame: Baseline and 24 weeks ]
    Biochemical response was defined as normalization of ALT level as compared to baseline.

  8. Number of Participants With Covalently Closed Circular Deoxyribonucleic Acid (cccDNA) Response at Week 72 of Therapy [ Time Frame: Baseline and 72 weeks for arm A and 48 weeks for arms B and C ]
    Virological cccDNA response was defined as reduction of intrahepatic cccDNA by 0.5 log in comparison to baseline at the end of follow up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic hepatitis B defined by the presence of HBsAg for at least 6 months prior to screening period. Co-infection with hepatitis D virus defined as positive anti-HDV antibodies for at least 3 months and positive for HDV-RNA within the screening period.
  • Liver biopsy performed within one year prior to screening or during screening period.
  • HBeAg negative
  • All women of childbearing potential must have a negative urine pregnancy test prior to enrolment.
  • Women must:

    1. Be menopausal for at least 2 years, or
    2. Be surgically sterile (total hysterectomy or bilateral ovariectomy or bilateral tubal ligation/clips or otherwise be incapable of pregnancy), or
    3. Not be heterosexually active during the study, or
    4. Agree to use a highly effective method of birth control (double barrier method or combination of barrier method with hormonal or intrauterine device) during the study and for 3 month after the last dosing of the investigational medicinal product.
  • Men must agree to use a highly effective method of birth control (double barrier methods or combination of barrier method with hormonal or intrauterine device in their women-partner) and not to donate a sperm during the study and for 3 month after the last dosing of the investigational medicinal product.
  • An understanding, ability and willingness to fully comply with study procedures and restrictions.
  • An ability to provide the written informed consent to participate in the study

Exclusion Criteria:

  • Decompensated liver disease (Child-Pugh-Score >6).
  • Co-infected with hepatitis C virus (HCV), or HIV.
  • Patients with presence of anti-HCV antibody and negative HCV RNA in two separate occasions within 12 months prior to screening could be enrolled into the study after sponsor written permission.
  • ALT > 6 ULN.
  • Creatinine clearance < 60 mL/min.
  • Total bilirubin > 2 mg/dL.
  • Confirmed contraindication for treatment with PEG-INF-a.
  • History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such as suspicious foci on imaging studies or elevated serum alpha-fetoprotein (AFP) levels. In patients with such findings, HCC will be ruled-out prior to screening for the present study.
  • One or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's Disease, other congenital or metabolic conditions affecting the liver, e.g. congestive heart failure or other severe cardiopulmonary disease). Patients with Gilbert's syndrome and Dubin-Johnson syndrome, two benign disorders associated with low-grade hyperbilirubinemia can be enrolled into the trial.
  • History of clinically evident pancreatitis.
  • History of alcohol or drug abuse within the preceding two years. For the purposes of the present study, alcohol abuse is arbitrarily defined as frequent consumption of alcoholic beverages with an average daily intake of more than 40 g of ethanol.
  • Participation in another study with an investigational drug within less than one month prior to this study or simultaneously to this study.
  • Patients who are unable or unwilling to follow the protocol requirements.
  • Patients with a history of seizures, central nervous system disorders or psychiatric disability thought to be clinically significant in the opinion of the investigator.
  • Patients with limited mental capacity to the extent that she/he cannot provide informed consent or information regarding adverse events of the study drug.
  • Clinically significant renal, respiratory or cardiovascular disease.
  • Pregnancy and lactation.
  • Patients who have previously participated in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02637999


Sponsors and Collaborators
Hepatera Ltd.
Investigators
Principal Investigator: Pavel Bogomolov, PhD LLC "Clinical Hospital of Tsentrosoyuz"

Publications:

Responsible Party: Hepatera Ltd.
ClinicalTrials.gov Identifier: NCT02637999     History of Changes
Other Study ID Numbers: MYR 201 (HDV)
First Posted: December 22, 2015    Key Record Dates
Results First Posted: April 13, 2018
Last Update Posted: April 13, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Infection
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis D
Hepatitis D, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Interferons
Interferon-alpha
Peginterferon alfa-2a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs